A Poolbeg Pharma Plc (LON:POLB) Investor Presentation for January 2024 presented by CEO Jeremy Skillington and outlines the company’s strategic shift towards generating sustainable revenue and achieving profitability.
It highlights Poolbeg’s focus on the development and commercialisation of innovative medicines for unmet medical needs. Key components include the leveraging of a proven leadership team with a successful track record in the pharmaceutical industry, a business model centred around revenue generation from commercial-stage products, and the development of high-value programs for partnering, including their lead candidate POLB 001 for cancer immunotherapy-induced CRS and severe influenza. The presentation also discusses the company’s strong financial position and ongoing strategic collaborations.
